Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 7/2013

01-07-2013 | Research Article

Association of BRCA1 promoter methylation with rs11655505 (c.2265C>T) variants and decreased gene expression in sporadic breast cancer

Authors: Tarique N. Hasan, B. Leena Grace, Gowhar Shafi, Rabbani Syed

Published in: Clinical and Translational Oncology | Issue 7/2013

Login to get access

Abstract

Objective

Breast cancer is the most common cancer and the main cause of cancer morbidity for women worldwide and is manifestation of abnormal genetic as well as epigenetic changes. Therefore, our aim was to study the association of BRCA1 promoter methylation with rs11655505 (c.−2265C/T) variants and gene expression in sporadic breast cancer.

Methods

Twenty-nine sporadic breast cancer tissues and 26 normal biopsies were used for this study. Genomic DNA and total RNA were extracted from paraffin-embedded tissue and SNP analysis performed. Methylation status of the BRCA1 promoter region was determined by methylation-specific PCR after sodium bisulfite modification of DNA.

Results

Among all clinical–pathological parameters only estrogen receptor –ve and +ve samples were significantly different for methylation status (P = 0.04). The genotypic (CC, CT and TT), allelic frequencies and methylation status had not been found to be significantly different from that of healthy controls (P = 0.67, 0.71 and 0.17, respectively). Similarly, methylated BRCA1 promoter was not found to be significantly different in different genotypes from unmethylated promoters between patients and controls. Interestingly, only heterozygous (CT) genotypes with low and normal expression of BRCA1 were significantly different for the differential expression of BRCA1 compared to controls (P = 0.004). However, in tumor samples decreased expression of gene is associated with methylated state of BRCA1 promoter [OR (95 % CI) = 25.09 (2.17–29.75); P = 0.01].

Conclusions

Our data suggest that both single nucleotide variations rs11655505 (c.–2265C/T) and the methylation status of BRCA1 are not associated significantly with the occurrence of sporadic breast cancer in studied population. However, decreased expression of gene is associated with the CT genotypes and the disease. But, in case of tumor samples, an association of methylation of the promoter to the decreased expression of BRCA1 gene suggests the possible role of methylation in gene silencing.
Literature
1.
2.
Parkin DM, Nambooze S, Wabwire-Mangen F, Wabinga HR (2010) Changing cancer incidence in Kampala, Uganda, 1991–2006. Int J Cancer 126:1187–1195PubMed
3.
Parkin DM, Whelan S, Ferlay J, Storm H (eds) (2005) Cancer incidence in five continents, vol I–VIII. Cancer Base No. 7. IARC Press, Lyon
4.
Bin Amer SM, Maqbool Z, Nirmal MS et al (2008) Gene expression profiling in women with breast cancer in Saudi population. Saudi Med J 29:507–513PubMed
5.
Murthy NS, Chaudhry K, Nadayil D, Agarwal UK, Saxena S (2009) Changing trends in incidence of breast cancer: Indian scenario. Indian J Cancer 46:73–74PubMedCrossRef
6.
Indian Council of Medical Research (2002) National Cancer Registry Programme of India—an overview. NCRP, Bangalore
7.
Couch FJ, DeShano ML, Blackwood MA et al (1997) BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 336:1409–1415PubMedCrossRef
8.
King MC, Marks JH, Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643–646PubMedCrossRef
9.
Fackenthal JD, Olopade OI (2007) Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 7:937–948PubMedCrossRef
10.
Matros E, Wang ZC, Lodeiro G, Miron A, Iglehart JD, Richardson AL (2005) BRCA1 promoter methylation in sporadic breast tumours: relationship to gene expression profiles. Breast Cancer Res Treat 91:179–186PubMedCrossRef
11.
Rice JC, Ozcelik H, Maxeiner P, Andrulis I, Futscher BW (2000) Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. Carcinogenesis 21:1761–1765PubMedCrossRef
12.
Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT (1995) Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 9:444–450PubMedCrossRef
13.
Catteau A, Morris JR (2002) BRCA1 methylation: a significant role in tumour development? Semin Cancer Biol 12:359–371PubMedCrossRef
14.
Esteller M, Fraga MF, Guo M et al (2001) DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet 10:3001–3007PubMedCrossRef
15.
Hedenfalk I, Duggan D, Chen Y et al (2001) Gene-expression profiles in hereditary breast cancer. N Engl J Med 344:539–548PubMedCrossRef
16.
van’t Veer LJ, Dai H, van de Vijver MJ et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536CrossRef
17.
Yu C, Zhou Y, Miao X, Xiong P, Tan W, Lin D (2004) Functional haplotypes in the promoter of matrix metalloproteinase-2 predicts risk of the occurrence and metastasis of esophageal cancer. Cancer Res 64:7622–7628PubMedCrossRef
18.
Freedman ML, Penney KL, Stram DO et al (2005) A haplotype-based case-control study of BRCA1 and sporadic breast cancer risk. Cancer Res 65:7516–7522PubMedCrossRef
19.
Verderio P, Pizzamiglio S, Southey MC et al (2010) A BRCA1 promoter variant (rs11655505) and breast cancer risk. J Med Genet 47:268–270PubMedCrossRef
20.
Chan KY, Liu W, Long JR et al (2009) Functional polymorphisms in the BRCA1 promoter influence transcription and are associated with decreased risk for breast cancer in Chinese women. J Med Genet 46:32–39PubMedCrossRef
21.
22.
Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93:9821–9826PubMedCrossRef
23.
Baldwin RL, Nemeth E, Tran H et al (2000) BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res 60:5329–5333PubMed
24.
Wei M, Grushko TA, Dignam J et al (2005) BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res 65:10692–10699PubMedCrossRef
25.
Futreal PA, Liu Q, Shattuck-Eidens D et al (1994) BRCA1 mutations in primary breast and ovarian carcinomas. Science 266:120–122PubMedCrossRef
26.
Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042–2054PubMedCrossRef
27.
Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415–428PubMedCrossRef
28.
Birgisdottir V, Stefansson OA, Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG, Eyfjord JE (2006) Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res 8:R38PubMedCrossRef
29.
Bosviel R, Garcia S, Lavediaux G et al (2012) BRCA1 promoter methylation in peripheral blood DNA was identified in sporadic breast cancer and controls. Cancer Epidemiol 36(3):e177–182
30.
Wong EM, Southey MC, Fox SB et al (2011) Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer. Cancer Prev Res (Phila) 4:23–33CrossRef
Metadata
Title
Association of BRCA1 promoter methylation with rs11655505 (c.2265C>T) variants and decreased gene expression in sporadic breast cancer
Authors
Tarique N. Hasan
B. Leena Grace
Gowhar Shafi
Rabbani Syed
Publication date
01-07-2013
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 7/2013
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-012-0968-y

Other articles of this Issue 7/2013

Clinical and Translational Oncology 7/2013 Go to the issue

Research Article

Upregulation of microRNA-224 confers a poor prognosis in glioma patients

Research Article

Increased expression of CD24 is associated with tumor progression and prognosis in patients suffering osteosarcoma

Educational Series - Blue Series

Lung adenocarcinoma in the era of targeted therapies: histological classification, sample prioritization, and predictive biomarkers

Brief Research Article

Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients

Research Article

Persistent elevated C-reactive protein after treatment is an independent marker of a poor prognosis in patients with hepatocellular carcinoma

Research Article

Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits